文献速递乳腺癌放疗消化道肿瘤放疗

乳腺癌放疗食管剂量体积效应与第二原发食管癌风险

Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer.
PubMed 文献 · Radiother Oncol · 2020-07-15

该病例对照研究嵌套于289,748例女性乳腺癌≥5年幸存者队列,重建252例食管癌病例和488例匹配对照的食管剂量体积直方图,发现食管中位剂量与食管癌风险相关,EOR/Gy为0.071(95%CI 0.018–0.206),且高剂量照射体积增大会增加鳞癌风险。

要点

  • 食管中位剂量是评估全组织学类型食管癌风险的最佳DVH指标,EOR/Gy=0.071。
  • 鳞癌中,V30每增加10%,Dmedian的EOR/Gy增加31%(95%CI 3%–205%,p=0.02)。
  • 调整DVH指标未实质改变DSPC的EOR/Gy,DSPC与V30存在边缘显著正交互(p=0.07)。

核心结论

  • 食管中位剂量每增加1 Gy,食管癌风险增加,EOR/Gy=0.071(95%CI 0.018–0.206)。
  • 高剂量照射体积增大会进一步增加鳞状细胞癌风险。

研究设计与样本

  • 病例对照研究嵌套于1943–2003年五国治疗的289,748例女性乳腺癌≥5年幸存者队列。
  • 纳入252例食管癌病例和488例匹配对照,中位随访13年(范围5–37年),重建全食管DVH。

主要发现

  • 全组织学类型合并分析中,食管中位剂量(Dmedian)统计性能最佳,EOR/Gy=0.071(95%CI 0.018–0.206)。
  • 鳞状细胞癌中,V30每增加10%,Dmedian的EOR/Gy增加31%(95%CI 3%–205%,p=0.02)。
  • 调整DVH指标未实质改变DSPC的EOR/Gy;DSPC与V30交互作用边缘显著(p=0.07)。

关键数值与推荐

  • 全组织学类型:Dmedian的EOR/Gy=0.071(95%CI 0.018–0.206)。
  • 鳞状细胞癌:V30每增加10%,EOR/Gy增加31%(95%CI 3%–205%,p=0.02)。
  • DSPC与V30交互作用p=0.07。

临床怎么用

  • 当前技术可更好地保护食管,对Dmedian和V30施加约束可能进一步降低食管癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the relationship between oesophagus dose-volume distribution and long-term risk of oesophageal cancer after radiation therapy for breast cancer. MATERIALS AND METHODS: In a case-control study nested within a cohort of 289,748 ≥5-year survivors of female breast cancer treated in 1943-2003 in five countries, doses to the second primary cancer (DSPC) and individual dose-volume histograms (DVH) to the entire oesophagus were reconstructed for 252 oesophageal cancer cases and 488 matched controls (median follow-up time: 13, range: 5-37 years). Using conditional logistic regression, we estimated excess odds ratios (EOR) of oesophageal cancer associated with DVH metrics. We also investigated whether DVH metrics confounded or modified DSPC-related -risk estimates. RESULTS: Among the DVH metrics evaluated, median dose (Dmedian) to the entire oesophagus had the best statistical performance for estimating risk of all histological types combined (EOR/Gy = 0.071, 95% confidence interval [CI]: 0.018 to 0.206). For squamous cell carcinoma, the most common subtype, the EOR/Gy for Dmedian increased by 31% (95% CI: 3% to 205%) for each increment of 10% of V30 (p = 0.02). Adjusting for DVH metrics did not materially change the EOR/Gy for DSPC, but there was a borderline significant positive interaction between DSPC and V30 (p = 0.07). CONCLUSION: This first study investigating the relationship between oesophagus dose-volume distribution and oesophageal cancer risk showed an increased risk per Gy for Dmedian with larger volumes irradiated at high doses. While current techniques allows better oesophagus sparing, constraints applied to Dmedian and V30 could potentially further reduce the risk of oesophageal cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Journy N, Schonfeld SJ, Hauptmann M, et al. Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. Radiother Oncol. 2020. PMID: 32679305. doi:10.1016/j.radonc.2020.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。